Evidence map›Paper›PMID 39574200›Full record

ReviewHuman genomics2024

Advancing understanding of human variability through toxicokinetic modeling, in vitro-in vivo extrapolation, and new approach methodologies.

Anna Kreutz, Xiaoqing Chang, Helena T Hogberg, Barbara A Wetmore

Abstract readReview
In one paragraph

Review in Human genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Perspectives on variability ofFrontiers in toxicology · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anna KreutzInotiv, 601 Keystone Park Drive, Suite 200, Morrisville, NC, 27560, USA. anna.kreutz@inotiv.com.
Xiaoqing ChangInotiv, 601 Keystone Park Drive, Suite 200, Morrisville, NC, 27560, USA.
Helena T HogbergNIH/NIEHS/DTT/NICEATM, Research Triangle Park, NC, 27560, USA.
Barbara A WetmoreOffice of Research and Development, Center for Computational Toxicology and Exposure, US Environmental Protection Agency, Research Triangle Park, NC, 27711, USA.

Funding

Novel Tools and Approaches Research ProgramZIAES103378 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI CRIZER, DAVID · 2022 to 2025
$11.2M
Intramural NIH HHS ZIA ES103378NIEHS NIH HHS HHSN273201500010CNIH HHS NIEHS Contract No. HHSN273201500010CNIH HHS ZIAES10274; ZIAES103378; NIEHS Contract No. HHSN273201500010CU.S. Environmental Protection Agency Office of Research and Development Chemical Safety for Sustainability National Research Program
6 · The paper itself

Abstract

The merging of physiology and toxicokinetics, or pharmacokinetics, with computational modeling to characterize dosimetry has led to major advances for both the chemical and pharmaceutical research arenas. Driven by the mutual need to estimate internal exposures where in vivo data generation was simply not possible, the application of toxicokinetic modeling has grown exponentially in the past 30 years. In toxicology the need has been the derivation of quantitative estimates of toxicokinetic and toxicodynamic variability to evaluate the suitability of the tenfold uncertainty factor employed in risk assessment decision-making. Consideration of a host of physiologic, ontogenetic, genetic, and exposure factors are all required for comprehensive characterization. Fortunately, the underlying framework of physiologically based toxicokinetic models can accommodate these inputs, in addition to being amenable to capturing time-varying dynamics. Meanwhile, international interest in advancing new approach methodologies has fueled the generation of in vitro toxicity and toxicokinetic data that can be applied in in vitro-in vivo extrapolation approaches to provide human-specific risk-based information for historically data-poor chemicals. This review will provide a brief introduction to the structure and evolution of toxicokinetic and physiologically based toxicokinetic models as they advanced to incorporate variability and a wide range of complex exposure scenarios. This will be followed by a state of the science update describing current and emerging experimental and modeling strategies for population and life-stage variability, including the increasing application of in vitro-in vivo extrapolation with physiologically based toxicokinetic models in pharmaceutical and chemical safety research. The review will conclude with case study examples demonstrating novel applications of physiologically based toxicokinetic modeling and an update on its applications for regulatory decision-making. Physiologically based toxicokinetic modeling provides a sound framework for variability evaluation in chemical risk assessment.

Indexed as

Models, BiologicalToxicokineticsAnimalsComputer SimulationHumansPharmacokineticsRisk AssessmentIn vitro-in vivo extrapolationLife-stageNew approach methodologiesPhysiologically based toxicokinetic modelToxicokinetic variability

Identifiers

PMID39574200
PMCPMC11580331

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.